Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $17.3 million.

  • Amphastar Pharmaceuticals' Profit After Tax fell 5708.53% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.6 million, marking a year-over-year decrease of 2922.42%. This contributed to the annual value of $159.5 million for FY2024, which is 1597.59% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Profit After Tax stood at $17.3 million for Q3 2025, which was down 5708.53% from $31.0 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Profit After Tax registered a high of $49.2 million during Q3 2023, and its lowest value of $5.0 million during Q1 2021.
  • Over the past 5 years, Amphastar Pharmaceuticals' median Profit After Tax value was $26.1 million (recorded in 2023), while the average stood at $27.7 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Profit After Tax skyrocketed by 70335.9% in 2021, and later crashed by 5708.53% in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Profit After Tax (Quarter) stood at $19.8 million in 2021, then surged by 71.62% to $33.9 million in 2022, then increased by 6.65% to $36.2 million in 2023, then grew by 4.97% to $38.0 million in 2024, then crashed by 54.3% to $17.3 million in 2025.
  • Its last three reported values are $17.3 million in Q3 2025, $31.0 million for Q2 2025, and $25.3 million during Q1 2025.